It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.
Seyfarth Shaw LLP is a full-service firm with more than 850 attorneys and 15 offices in the United States, London, Shanghai, Hong Kong, Melbourne, and Sydney, offering a national platform and an international gateway to serve our clients’ changing business and legal needs in corporate, employee benefits, employment, litigation, and real estate. Our attorneys provide thoughtful, strategic, practical legal counsel to clients of all sizes across all industries, delivering excellent legal service, sophisticated technology and process improvement solutions. Our clients range from Fortune 100 to midsize companies, and include publicly traded and privately held companies and various types of funds.
Dean L. Fanelli, Ph.D. is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office. Dr. Fanelli’s practice focuses on the chemical, pharmaceutical, and biotechnology industries and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions, and inter partes review and post grant review proceedings. Dr. Fanelli also focuses his practice on Paragraph IV litigation strategies, Hatch-Waxman litigation, and biosimilar market assessment and litigation strategy.
Dr. Fanelli’s focus is on pharmaceutical and chemical related technologies including those in the fields of new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices. He also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as Paragraph IV ANDA analyses and associated Hatch-Waxman Paragraph IV litigation.
Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society. He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.
Dr. Fanelli graduated from The George Washington University Law School and received his Ph.D. in Organic Chemistry from Temple University, after receiving his B.S. in Chemistry from Villanova University
Dr. Geoff Kuziemko is a Partner at O’Melveny & Myers LLP where he focuses on assisting clients, primarily in the life sciences sector, with intellectual property and technology-intense transactions. His work runs the gamut of complex transactions, from out-bound license and in-bound license, development, commercialization, strategic alliance and joint venture, collaboration, and profit sharing agreements to commercial agreements for distribution, manufacture, and supply, as well as intellectual property due diligence for strategic acquisitions and financings involving life sciences businesses, products, and patents.
Thomas Haag is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office where he co-chairs the firm’s Chemical & Life Sciences Patent Team. His practice focuses on pharmaceutical and biotechnology patent litigation, due diligence, prosecution and licensing/transactional matters; and in particular Hatch-Waxman litigation and Biosimilars related matters.
He has extensive experience creating and strategically managing large patent portfolios, as well as drafting and negotiating biomedical patent licenses, asset purchase agreements and joint-development agreements. His technical expertise is in molecular biology related technologies including those in the fields of immuno-oncology, cancer/infectious disease vaccines, nucleic acid-based therapeutics, stem-cell therapeutics, gene editing and therapy, epigenetics, transgenic plants, next generation sequencing (NGS), biologics and biosimilars.
Dr. Haag has firsthand experience in translating biotechnologies into successful commercial ventures. While at his previous firm, Fanelli Haag, he served as acting CEO of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Fanelli Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015.
Dr. Haag graduated from The George Washington University Law School with honors, where he also received the ABA/BNA Award for Excellence in the Study of Intellectual Property Law. Dr. Haag received a B.S. in Biology and Ph.D. in Molecular, Cell & Developmental Biology from UCLA where he was an NIH Pre-Doctoral Fellow in Genetic Mechanisms.